TY - JOUR
T1 - Curcumin based nanomedicines as efficient nanoplatform for treatment of cancer
T2 - New developments in reversing cancer drug resistance, rapid internalization, and improved anticancer efficacy
AU - Khan, Shahzeb
AU - Imran, Muhammad
AU - Butt, Tariq Tahir
AU - Ali Shah, Syed Wadood
AU - Sohail, Muhammad
AU - Malik, Arif
AU - Das, Srijit
AU - Thu, Hnin Ei
AU - Adam, Aishah
AU - Hussain, Zahid
N1 - Funding Information:
The authors would like to acknowledge “Institute of Research Management & Innovation (IRMI)”, Universiti Teknologi MARA (UiTM), Malaysia for providing LESTARI grant (600-IRMI/DANA 5/3/LESTARI (0007/2016)) and Department of Pharmacy, University of Malakand, Pakistan for their support in writing this review article.
Funding Information:
The authors would like to acknowledge “ Institute of Research Management & Innovation (IRMI) ”, Universiti Teknologi MARA (UiTM), Malaysia for providing LESTARI grant ( 600-IRMI/DANA 5/3/LESTARI (0007/2016 )) and Department of Pharmacy, University of Malakand, Pakistan for their support in writing this review article.
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/10
Y1 - 2018/10
N2 - Background: Cancer is a group of diseases involving an abnormal growth of cells which tend to proliferate in an uncontrolled fashion and in some cases metastasize to the surrounding tissues (malignancy). Resistance to chemotherapy is typically intrinsic (heterogeneity); however, acquired resistance has also become prevelant due to multiple factors including expression of energy-dependent transporters causing expulsion of internalized drug contents extracellular, insensitivity of tumor cells to drug-induced apoptosis, and induction of drug-detoxifying mechanisms. Curcumin (CUR) has gained widespread recognition due to remarkable anticancer, anti-mutagenic, and anti-metastasizing potentials via downregulation of proliferation of cancer cells and induction of apoptosis. Nevertheless, pharmaceutical significance and therapeutic feasibility of CUR is restricted due to intrinsic physicochemical characteristics including poor aqueous solubility, inadequate biological stability, low bioavailability, and short half-life. Scope and approach: Owing to these pharmaceutical limitations of CUR, nanodelivery systems have attained remarkable fascination in the recent years. Therefore, this review was aimed to overview and critically ponders recent developments in improving anticancer viability of CUR. Key findings and conclusion: Critical analysis of the literature revealed that nanodelivery systems showed promising efficiency in achieving tumor specific targetability, maximizing internalization of drugs into cancer cells, mitigating tumor metastasis, as well as improving anticancer efficacy of CUR. Moreover, nanocarrier-mediated improved pharmacokinetics, drug accumulation, induced promising cytotoxicity, and enhanced anticancer efficacy by suppressing Egr-1 induction, Mitogen-activated protein kinase (MAPK) pathway, and protein tyrosine kinase (PTK) cascades while mitigating the progression of tumor, have also been discussed.
AB - Background: Cancer is a group of diseases involving an abnormal growth of cells which tend to proliferate in an uncontrolled fashion and in some cases metastasize to the surrounding tissues (malignancy). Resistance to chemotherapy is typically intrinsic (heterogeneity); however, acquired resistance has also become prevelant due to multiple factors including expression of energy-dependent transporters causing expulsion of internalized drug contents extracellular, insensitivity of tumor cells to drug-induced apoptosis, and induction of drug-detoxifying mechanisms. Curcumin (CUR) has gained widespread recognition due to remarkable anticancer, anti-mutagenic, and anti-metastasizing potentials via downregulation of proliferation of cancer cells and induction of apoptosis. Nevertheless, pharmaceutical significance and therapeutic feasibility of CUR is restricted due to intrinsic physicochemical characteristics including poor aqueous solubility, inadequate biological stability, low bioavailability, and short half-life. Scope and approach: Owing to these pharmaceutical limitations of CUR, nanodelivery systems have attained remarkable fascination in the recent years. Therefore, this review was aimed to overview and critically ponders recent developments in improving anticancer viability of CUR. Key findings and conclusion: Critical analysis of the literature revealed that nanodelivery systems showed promising efficiency in achieving tumor specific targetability, maximizing internalization of drugs into cancer cells, mitigating tumor metastasis, as well as improving anticancer efficacy of CUR. Moreover, nanocarrier-mediated improved pharmacokinetics, drug accumulation, induced promising cytotoxicity, and enhanced anticancer efficacy by suppressing Egr-1 induction, Mitogen-activated protein kinase (MAPK) pathway, and protein tyrosine kinase (PTK) cascades while mitigating the progression of tumor, have also been discussed.
KW - Active targeting
KW - Cancer
KW - Curcumin
KW - Nanotechnology
KW - Passive targeting
KW - Targeted delivery
KW - Upgradation of anticancer efficacy
UR - http://www.scopus.com/inward/record.url?scp=85050910410&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050910410&partnerID=8YFLogxK
U2 - 10.1016/j.tifs.2018.07.026
DO - 10.1016/j.tifs.2018.07.026
M3 - Review article
AN - SCOPUS:85050910410
SN - 0924-2244
VL - 80
SP - 8
EP - 22
JO - Trends in Food Science and Technology
JF - Trends in Food Science and Technology
ER -